Garvan Institute of Medical Research

Garvan Institute of Medical Research

Genetic disease-focused biomedical research institute

Overview

Garvan Institute of Medical Research conducts biomedical research to understand how genes, molecules, and cells influence health and disease, aiming to prevent and treat major illnesses. It combines fundamental science with strong clinical collaborations to translate discoveries into medical advances. What sets Garvan apart is its sustained, long-term work that integrates laboratory research with direct clinical interactions across a range of diseases, not just one specialty. Its goal is to prevent, treat, or cure major diseases such as cancer, diabetes/obesity, neurological disorders, osteoporosis, and immunological diseases by uncovering mechanisms and developing new therapies.

About Garvan Institute of Medical Research

Simplify's Rating
Why Garvan Institute of Medical Research is rated
C+
Rated C on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Biotechnology

Healthcare

Company Size

501-1,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Sydney, Australia

Founded

1963

Get referred to Garvan Institute of Medical Research

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • NHMRC awarded Garvan’s autoimmune centre funding on 7 September 2026, extending five-year support.
  • Garvan secured NHMRC funding boosts on 10 August 2026 for genomic and immune discoveries.
  • Garvan announced new cancer labs and recruitment in August 2026, signaling continued scientific expansion.

What critics are saying

  • Garvan’s revenue depends on grants and philanthropy; one funding gap can freeze programs quickly.
  • Revelio shows 663 employees in March 2026 and only 16 postings, signaling hiring caution.
  • If translational bets like PatientSeek or CAR-T fail, Garvan remains a research-only cost center.

What makes Garvan Institute of Medical Research unique

  • Garvan’s autoimmune CRE under Chris Goodnow targets somatic mutation biology, not generic immunology.
  • Its Genomics Platform joined Parse Biosciences in July 2026, expanding regional single-cell access.
  • Garvan pairs discovery research with clinical trial networks, including Parkinson’s stratification and cancer studies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Parental Leave

Flexible Work Hours

Professional Development Budget

Conference Attendance Budget

Employee Discounts

Company News

BioSpace
Feb 22nd, 2023
C4Xd And Garvan Institute Of Medical Research Report Successful Patient Stratification Approach Using C4Xd'S New Precision Medicine Platform Patientseek

First validation of C4XD's patient sub-groups through a Garvan-led retrospective clinical trial analysis. Promising initial result paves way for novel approaches in Parkinson's disease stratification. Launch of PatientSeek platform enables stratification of patients to identify the right patient for the right medicine

Recently Posted Jobs

Sign up to get curated job recommendations

Garvan Institute of Medical Research is Hiring for 11 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →